Abstract 6074
Background
In Spain, we do not have real-time information about cancer survivors follow-up by their family doctor. The main objective of this study is to describe the characteristics and quality of life of cancer survivors followed at a primary care center in Northwest of Spain.
Methods
An individual interview was conducted with 100 survivors of breast or colon or lung cancer, all of them free of disease five or more years after their initial diagnosis. Socio-demographic variables, care plan and global quality of life assessment (using the EORTC QLQ-C30 questionnaire), were collected.
Results
We analyzed socio-demographic data of 72 women and 28 men. At the time of the interview, their median age was 66-years-old (37-99), most were married (61%), had primary studies (58%) and do not work (77 %). We analyzed aspects related to their global quality of life by using the EORTC QLQ-C30 questionnaire. A third (36%), acknowledged that their cancer diagnosis had influenced their employment status. More than 50% of survivors recognized asthenia and/or pain at the time of the interview, and at least a 15% and 20% of these cases respectively, related these symptoms to their previous diagnosis of cancer. More than a half (56%) acknowledged their previous cancer diagnosis had changed their lifes, and to a lesser extent the life of their family (28%) and economy. A 64% of the interviewed survivors considered that their enjoyed a good or a very good quality of life. Most ot the cancer survivors (75%) described themselves as cured people.
Conclusions
Most survivors recognized that their cancer diagnosis changed their lives, and up to a third of the cases also their work situation. However, the majority of survivors report a globally good quality of life and describe themselves as cured people.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Begoña Graña.
Funding
SEOM - "Oncovida" scholarship.
Disclosure
B. Grana Suarez: Research grant / Funding (institution), Travel / Accommodation / Expenses: Amgen; Travel / Accommodation / Expenses: Celgene; Research grant / Funding (institution): Roche; Travel / Accommodation / Expenses: Servier. All other authors have declared no conflicts of interest.
Resources from the same session
3212 - Multigene panel testing results for hereditary breast cancer in 1325 individuals: implications for gene selection and considerations for guidelines.
Presenter: Georgios Tsaousis
Session: Poster Display session 3
Resources:
Abstract
2591 - PIK3R5 genetic predictors of hypertension induced by VEGF-pathway inhibitors
Presenter: Julia Quintanilha
Session: Poster Display session 3
Resources:
Abstract
4377 - ERBB2 mRNA as a predictor in HER2-positive (HER2+)/hormone receptor-positive (HR+) metastatic breast cancer (BC) treated with HER2 blockade in combination with endocrine therapy (ET): a retrospective analysis of the ALTERNATIVE and SOLTI-PAMELA trials.
Presenter: Nuria Chic
Session: Poster Display session 3
Resources:
Abstract
3439 - Early on-treatment vs pre-treatment tumor transcriptomes as predictors of response to neoadjuvant therapy for HER2-positive inflammatory breast cancer
Presenter: Sonia Pernas
Session: Poster Display session 3
Resources:
Abstract
2512 - AXL expression predicts poor prognosis and lack of efficacy of anti-angiogenic and anti-epidermal growth factor receptor (EGFR) agents in patients (pts) with RAS wild type (WT) metastatic colorectal cancer (mCRC)
Presenter: Claudia Cardone
Session: Poster Display session 3
Resources:
Abstract
4061 - Prevalence of EGFR mutations and its correlation with Egyptian patients’ human kinetics (PEEK Study)
Presenter: Adel Ibrahim
Session: Poster Display session 3
Resources:
Abstract
2547 - Evaluation of tumor microenvironment identifies immune correlates of response to combination immunotherapy with margetuximab (M) and pembrolizumab (P) in HER2+ gastroesophageal adenocarcinoma (GEA)
Presenter: Sergio Rutella
Session: Poster Display session 3
Resources:
Abstract
4671 - Clinicopathological and molecular criteria assessment for the screening of hypermutated proficient mismatch repair (pMMR) colorectal cancers (CRC) with exonucleasic domain POLE (edPOLE) mutations (mt).
Presenter: Benoit Rousseau
Session: Poster Display session 3
Resources:
Abstract
3862 - Tumor mutation burden and microsatellite instability in colorectal cancer
Presenter: Francesca Fenizia
Session: Poster Display session 3
Resources:
Abstract
4614 - Predictors of Response to Checkpoint Inhibitors in Naïve and Ipilimumab-Refractory Melanoma
Presenter: Domenico Mallardo
Session: Poster Display session 3
Resources:
Abstract